#Sunlenca
Cameron's Sunlenca Prank Ends in TEARS
November 8, 2026 at 5:21 PM
#Saude 💰 Injeção semestral contra HIV custa até R$ 20.900

❌ Anvisa registra teto de R$ 20.914,22 para o Sunlenca; medicamento não é vendido em farmácias nem está disponível no SUS

⬇️ Leia no Poder360:
www.poder360.com.br/poder-saude/...
Injeção semestral contra HIV custa até R$ 20.900
Anvisa registra teto de R$ 20.914,22 para o Sunlenca; medicamento não é vendido em farmácias nem está disponível no SUS. Leia no Poder360.
www.poder360.com.br
October 19, 2026 at 6:57 PM
Injeção semestral contra HIV custa até R$ 20.900
Injeção semestral contra HIV custa até R$ 20.900
Anvisa registra teto de R$ 20.914,22 para o Sunlenca; medicamento não é vendido em farmácias nem está disponível no SUS. Leia no Poder360.
www.poder360.com.br
October 19, 2026 at 6:53 PM
House's Sunlenca Prank Ends in TEARS
September 17, 2026 at 8:46 AM
A Anvisa aprovou nessa segunda (12) o uso do medicamento Sunlenca (lenacapavir) para prevenção do HIV-1, como profilaxia pré-exposição (PrEP). O fármaco tem alta eficácia contra o vírus e, além da apresentação em comprimido, para uso oral, está disponível como injeção.
January 13, 2026 at 11:08 AM
"UNAIDS said that the number of #AIDS death last year — an estimated 630,000 — was at its lowest since peaking in 2004, suggesting the world is now at “a historic crossroads” and has a chance to end the epidemic." #lenacapavir #Sunlenca #HIV www.thecanadianpressnews.ca/health/a-twi...
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
MEXICO CITY (AP) — It’s been called the closest the world has ever come to a vaccine against the AIDS virus.
www.thecanadianpressnews.ca
December 1, 2024 at 2:40 PM
Lenacapavir Injection (SUNLENCA) 0.4635g/1.5ml × 2 Vials – For Laboratory Research Use Only

SUNLENCA Lenacapavir Injection supplies 0.4635g active ingredient per 1.5ml vial, 2 vials per box. Produced by Patheon Italia S.p.A., approved under China NMPA HJ20240170. Intended exclusively for…
Lenacapavir Injection (SUNLENCA) 0.4635g/1.5ml × 2 Vials – For Laboratory Research Use Only
SUNLENCA Lenacapavir Injection supplies 0.4635g active ingredient per 1.5ml vial, 2 vials per box. Produced by Patheon Italia S.p.A., approved under China NMPA HJ20240170. Intended exclusively for laboratory research applications. Supports wholesale and retail orders.(For wholesale prices, other specifications and uses, please consult our staff)
arizona-mall.com
August 1, 2025 at 3:27 PM
Very promising results from LTZ - just 2 injections per year to maintain HIV at undetectable levels.
www.aidsmap.com/news/mar-202...
Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment
Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented yesterd...
www.aidsmap.com
March 16, 2025 at 8:56 AM
Here we go: Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. Says it costs $40. About right.
December 13, 2024 at 12:52 AM
"...the drug costs more than $40,000 a year in the U.S. ... Gilead said it was too early to say how much Sunlenca would cost for prevention in poorer countries." i merely remark
That this disease went from an incurable 100% death sentence to something preventable in the space of my lifetime is stunning to me. Compare to early modern Europe, where smallpox and plague were endemic for generations.

Below, a discussion of the test results. I truly never thought I'd see this.
Experts say a twice-yearly injection that offers 100% protection against HIV is 'stunning'
A study shows that a twice-yearly shot was 100% effective in preventing new HIV infections in women in Africa.
apnews.com
August 6, 2025 at 5:16 PM
"Lenacapavir is available in the United States. It is available under two brand names depending on its intended use:For HIV Prevention (PrEP): Marketed under the brand name Yeztugo...For HIV Treatment: Marketed under the brand name Sunlenca..."
June 6, 2026 at 3:47 PM
#Lenacapavir " #Anvisa cautioned that, although the drug has been approved, it still depends on the definition of a maximum price by Brazil’s Drug Market Regulation Chamber (CMED). Its inclusion in #Brazil’s public healthcare system." #Bioethics

www.brasildefato.com.br/2026/01/13/b...
Brazil’s health agency Anvisa approves long-acting HIV prevention drug with six-month injection - Brasil de Fato
Brazil’s National Health Surveillance Agency (Anvisa), the federal body responsible for regulating medicines, vaccines, and health products, approved on Monday (12) the use of Sunlenca (lenacapavir) f...
www.brasildefato.com.br
January 15, 2026 at 2:36 PM
Excellent news. BARDA awards grant to Shionogi to study a long-acting anti-viral to prevent COVID-19.

This comes on the heels of the amazing success in clinical trials of SUNLENCA (lenacapavir) in preventing HIV/AIDS.
January 17, 2025 at 4:49 PM